Ovarian Clear Cell Cancers: Are There Effective Treatment Strategies and Reliable Prognostic Factors?

Shittu Adamu Muhammad, Olaoye Stephen Oyewole, Bello Alhaji Mohammed
In: Jewel Journal of Medical Sciences · 2022 · vol. 3(1) , pp. 17–26 · doi:10.56167/jjms.2022.0301.02 · W4312317030
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher

Abstract

Ovarian clear cell cancers (OCCC) represent 5–25% of ovarian cancers. Histologic diagnosis remains a significant challenge, often misclassifying the cancers. These tumours tend to present at earlier stages, and their aetiology is linked to endometriosis and genetic aberrations such as ARID1A and PIK3CA mutations. When compared, stage for the stage with other epithelial ovarian cancers, patients with early-stage OCCC have a better prognosis than patients with high-grade serous tumours. Patients with Stage IC–IV have a relatively poor prognosis, and efforts should centre on discovering more effective treatment strategies. Ovarian CCC is a biologically distinct entity, different from high-grade serous epithelial ovarian cancers (EOC). Future research is needed to explore targeted therapy’s role in managing ovarian CCC.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (13)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK